ProfileGDS5678 / 1424314_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 71% 65% 64% 63% 54% 60% 60% 62% 65% 67% 63% 62% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7444362
GSM967853U87-EV human glioblastoma xenograft - Control 24.434271
GSM967854U87-EV human glioblastoma xenograft - Control 33.9151965
GSM967855U87-EV human glioblastoma xenograft - Control 43.8434364
GSM967856U87-EV human glioblastoma xenograft - Control 53.7014763
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.418554
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.700260
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5970660
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7238562
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8846665
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0859367
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7265463
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7101562
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8592464